Relmada Therapeutics Boosts Authorized Shares to 200 Million
Summary
Relmada Therapeutics' shareholders have approved an increase in authorized common stock from 150 million to 200 million shares. This action follows a PRE 14A filing on April 6th that proposed this change. The 50 million share increase provides the company with significant flexibility for future capital raises, potential acquisitions, or stock-based compensation. This move is particularly relevant given the company's recent history of substantial financings, including a $160 million private placement and an S-3 filing for the resale of 33.68 million shares, aimed at strengthening its cash position and resolving its going concern status. Investors should watch for future prospectus supplements (424B filings) that would indicate actual share sales under the company's existing shelf registration and ATM program.
At the time of this announcement, RLMD was trading at $7.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $760.5M. The 52-week trading range was $0.52 to $8.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.